Literature DB >> 6417019

Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide.

I Vodopija, Z Baklaic, P Hauser, P Roelants, F E André, A Safary.   

Abstract

The immunogenicity and the reactivity of two bivalent (AC) and two tetravalent (ACW135Y) meningococcal vaccines containing either the O-acetyl-positive or the O-acetyl-negative group C polysaccharide were compared in healthy adolescent and adult volunteers. The vaccines contained high-molecular-weight, purified capsular meningococcal polysaccharides and were administered subcutaneously at a dose of 50 micrograms for each polysaccharide. Reactivity was low for all vaccines, and the tetravalent vaccines were not significantly more reactive than the bivalent vaccines. Immunogenicity was measured by assay of bactericidal antibodies in pre- and postvaccination sera. More than 90% of the vaccines had at least a fourfold increase in the bactericidal antibody titer against each group of meningococcus represented in the vaccines. Addition of polysaccharide W135 and polysaccharide Y to polysaccharides A and C did not alter the immunogenicity of the latter polysaccharides. Thus, there is no evidence of antigenic competition with the tetravalent vaccine. Comparison of the antibody response to the O-acetyl-positive and the O-acetyl-negative variants of group C polysaccharide in the bivalent vaccines, as measured by both bactericidal and enzyme-linked immunosorbent assays, indicates that in adults, the two types of group C polysaccharide are similarly immunogenic.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6417019      PMCID: PMC264470          DOI: 10.1128/iai.42.2.599-604.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  10 in total

1.  Analysis of a bivalent meningococcal vaccine (A + C). Part I. Analytical and safety data.

Authors:  M L Anhoury; M Arickx; B Boon; P Crooy; R de Neys; M Dewez; D Gilles; J Goossens; R Liveyns; P Roelants
Journal:  Ann Soc Belg Med Trop       Date:  1979-09

2.  Meningococcal disease in New York City, 1973 to 1978. Recognition of groups y and W-135 as frequent pathogens.

Authors:  E I Galaid; C E Cherubin; J S Marr; S Schaefler; J Barone; W Lee
Journal:  JAMA       Date:  1980-11-14       Impact factor: 56.272

3.  Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults.

Authors:  J M Griffiss; B L Brandt; P L Altieri; G B Pier; S L Berman
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

4.  Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation.

Authors:  J Armand; F Arminjon; M C Mynard; C Lafaix
Journal:  J Biol Stand       Date:  1982-10

5.  Meningococcal group C subgroup determinant detected by immunofluorescence.

Authors:  M A Apicella; H A Feldman
Journal:  Proc Soc Exp Biol Med       Date:  1976-07

6.  Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers.

Authors:  M P Glode; E B Lewin; A Sutton; C T Le; E C Gotschlich; J B Robbins
Journal:  J Infect Dis       Date:  1979-01       Impact factor: 5.226

7.  Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children.

Authors:  R Gold; M L Lepow; I Goldschneider; T F Draper; E C Gotshlich
Journal:  J Infect Dis       Date:  1979-11       Impact factor: 5.226

8.  Meningococcal disease and its control with meningococcal polysaccharide vaccines.

Authors:  A Galazka
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

9.  Group C Neisseria meningitidis variant polysaccharide vaccines in children.

Authors:  M C Steinhoff; E B Lewin; E C Gotschlich; J B Robbins
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

10.  Meningococcal disease in Scandinavia.

Authors:  H Peltola; K Jónsdóttir; A Lystad; C J Sievers; I Kallings
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-29
  10 in total
  4 in total

Review 1.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Conjugates of group A and W135 capsular polysaccharides of neisseria meningitidis bound to recombinant Staphylococcus aureus enterotoxin C1: preparation, physicochemical characterization, and immunological properties in mice.

Authors:  Zhigang Jin; Gregory A Bohach; Joseph Shiloach; Scott E Norris; Darón I Freedberg; Claudia Deobald; Bruce Coxon; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Meningococcal vaccines in China.

Authors:  Yinghua Xu; Yanan Li; Shanshan Wang; Maoguang Li; Miao Xu; Qiang Ye
Journal:  Hum Vaccin Immunother       Date:  2021-02-10       Impact factor: 3.452

Review 4.  Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines.

Authors:  Francesco Berti; Riccardo De Ricco; Rino Rappuoli
Journal:  Molecules       Date:  2018-06-02       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.